Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Organon (OGN – Research Report) and Sarepta Therapeutics (SRPT – Research Report).
Organon (OGN)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on Organon, with a price target of $18.00. The company’s shares closed last Thursday at $18.62.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
Currently, the analyst consensus on Organon is a Hold with an average price target of $20.25.
See Insiders’ Hot Stocks on TipRanks >>
Sarepta Therapeutics (SRPT)
Needham analyst Gil Blum reiterated a Buy rating on Sarepta Therapeutics today and set a price target of $169.00. The company’s shares closed last Thursday at $124.89.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $145.38 average price target, representing a 16.7% upside. In a report issued on February 1, Bank of America Securities also maintained a Buy rating on the stock with a $164.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OGN:
